Target Name: CCND3
NCBI ID: G896
Other Name(s): G1/S-specific cyclin D3 | cyclin D3 | G1/S-specific cyclin-D3 | CCND3 variant 2 | Cyclin D3 | G1/S-specific cyclin-D3 (isoform 4) | CCND3 variant 3 | Cyclin D3, transcript variant 3 | G1/S-specific cyclin-D3 (isoform 2) | CCT-alpha | Cyclin D3, transcript variant 6 | G1/S-specific cyclin-D3 (isoform 3) | CCND3 variant 6 | Cyclin D3, transcript variant 4 | CCND3 variant 4 | TCP-1-alpha | CCND3_HUMAN | D3-type cyclin | Cyclin D3, transcript variant 2 | G1/S-specific cyclin-D3 (isoform 5)

CDK3: A Potential Drug Target for Cancer

Cyclin D3 (CDK3) is a key transcription factor that plays a crucial role in the regulation of cell cycle progression and the maintenance of stem cell properties. CDK3 is a G1-specific cyclin, which means that it is primarily active during the G1 phase of the cell cycle. Despite its importance for cell cycle regulation, CDK3 has not been well studied, and there are limited drugs that are currently available that target this protein.

The discovery of CDK3 as a potential drug target

The search for new treatments for cancer has led to the identification of CDK3 as a potential drug target. CDK3 has been shown to be involved in the regulation of cell growth, and studies have suggested that inhibiting its activity may be a useful way to treat certain types of cancer.

One of the key reasons for the potential of CDK3 as a drug target is its involvement in the regulation of cell cycle progression. CDK3 is a transcription factor that regulates the expression of genes that are involved in cell cycle progression, including genes that encode the components of the microtubules that make up the cell nucleus.

Studies have shown that CDK3 plays a critical role in the regulation of mitosis, the process by which a cell divides. During mitosis, CDK3 is involved in the maintenance of the microtubules that provide support to the cell nucleus during the cell division process.

In addition to its role in cell division, CDK3 has also been shown to be involved in the regulation of cell growth. Studies have shown that CDK3 can inhibit the activity of the oncogene baderonimab, which is involved in the regulation of cell growth and has been shown to be a potential drug target for cancer.

The potential benefits of targeting CDK3

Targeting CDK3 as a drug target have the potential to treat a wide range of cancer types. Because CDK3 is involved in the regulation of cell cycle progression and cell growth, inhibiting its activity may be a useful way to treat cancers that are characterized by these processes , such as breast cancer, lung cancer, and ovarian cancer.

In addition to its potential as a cancer treatment, CDK3 has also been shown to have potential as a biomarker. The expression of CDK3 has been shown to be associated with the development and progression of certain types of cancer, and may be a useful biomarker for the diagnosis and prognosis of these cancers.

The development of small molecules that target CDK3 is an active area of 鈥嬧?媟esearch, and there is a growing interest in the potential of these molecules as treatments for cancer. Some of the most promising small molecules that target CDK3 come from a collaboration between the pharmaceutical company Novartis and the academic research center of the University of Zurich.

Conclusion

CDK3 is a protein that plays a critical role in the regulation of cell cycle progression and has been shown to be involved in the regulation of cell growth. Despite its importance for cell cycle regulation, CDK3 has not been well studied, and there are limited drugs that are currently available that target this protein. The potential of CDK3 as a drug target and biomarker make it an attractive target for future research. Further studies are needed to understand the full role of CDK3 in cell biology and to develop new treatments for cancer.

Protein Name: Cyclin D3

Functions: Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed:8114739). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase (PubMed:8114739). Hypophosphorylates RB1 in early G(1) phase (PubMed:8114739). Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals (PubMed:8114739). Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex (PubMed:16782892). Shows transcriptional coactivator activity with ATF5 independently of CDK4 (PubMed:15358120)

More Common Targets

CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2